|
|
Article: Beacon Equity Research Initiates Coverage of Dermisonics, Inc. Projecting 12-Month Share Price Growth Target of $1.81; Report Cites Global Market Potential for Dermisonics' Painless Drug Delivery Platform Technology for Insulin and Other Drugs.(Industry Overview)
- Article from:
- Business Wire
- Article date:
- November 14, 2005
CopyrightCOPYRIGHT 2005 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
WEST CONSHOHOCKEN, Pa. -- Dermisonics, Inc. (OTCBB:DMSI)(FWB:FQC), a developer of painless, injection-free, ultrasonic transdermal drug-delivery patches and technologies with broad pharmaceutical and consumer applications, today announced that leading investment analyst Beacon Equity Research has initiated paid, comprehensive research coverage with an extensive, 40-page report that details the Company's proprietary technology, with projections of a 12-month target share price of $1.81, a significant increase over recent share prices.
The report details Dermisonics' program to develop next-generation, advanced drug delivery platform technologies involving a ...